Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
BPC-157 + TB-500 blend (the "Wolverine" stack) - the two most-studied recovery peptides pre-combined in a single vial
ANNLR | Annular Research
The peptide influences how newly synthesized collagen arranges itself, promoting the parallel architecture that provides tensile strength
That Oral and Injectable Routes Are Equivalent Some rodent studies using oral gavage showed effects comparable to injection
International Regulatory Landscape Healthcare Provider Considerations Healthcare providers who prescribe or recommend BPC-157 face potential: Disciplinary action from state medical boards Medical license implications (sanctions, restrictions, suspension) Malpractice liability (insurance often excludes experimental treatments) Federal regulatory enforcement Research and Access Legitimate research pathways: Investigational New Drug (IND) application required for human research Institutional Review Board (IRB) approval required GMP standards required for research-grade materials Current access: Research peptide suppliers (variable quality) Some compounding pharmacies (legal status varies) Clinical trials (limited availability) Why This Regulatory Status Exists BPC-157's prohibition stems from: Limited clinical data Only small pilot studies published (~28 human subjects total)
US$ 24.04
US$ 21.96
US$ 21.42
US$ 26.57
US$ 29.71